Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
1
25%
Ph phase_3
2
50%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)

NCT05084911
completedphase_1

Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study

NCT01156389
completedphase_2

Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

NCT05633420
completedphase_3

Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)

NCT04783051

Clinical Trials (4)

Showing 4 of 4 trials
NCT05084911Phase 3

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)

Completed
NCT01156389Phase 1

Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study

Completed
NCT05633420Phase 2

Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

Completed
NCT04783051Phase 3

Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4